Plasma D-dimer are measurable degradation products of cross-linked fibrin, whose levels increase in presence of a blood clot but also in various other situations associated with activated coagulation. Over the last 30 years, D-dimer have revealed their main strength as a diagnostic tool in venous thromboembolic diseases (VTE). Their central clinical usefulness indeed resides in their role as an exclusion test in patients with suspected VTE [@bib0055], [@bib0060]. Multiple large scale prospective management outcome trials have confirmed the safety of excluding pulmonary embolism (PE) and deep vein thrombosis (DVT) by a negative D-dimer test associated with a non-high pretest clinical probability [@bib0065]. Some more restricted evidence also suggests that D-dimer could allow ruling out aortic dissection in association with a low AAD-RS score [@bib0070]. Finally, D-dimer are used as a diagnostic tool in the setting of disseminated intravascular coagulation (DIC), and have been integrated in the latest ISTH overt-DIC diagnostic criteria [@bib0075].

D-dimer have also been studied as a prediction tool in different settings such as prediction of VTE occurrence in acutely ill hospitalized medical patients to guide thromboprophylaxis prescription, or prediction of VTE recurrence after a first episode of unprovoked VTE to tailor duration of anticoagulant treatment. In acutely ill medical inpatients, a post-hoc analysis of the MAGELLAN trial (*n*  = 7581) showed that a D-dimer level \> 2 times the upper limit of normal range was an independent predictor of VTE events (OR compared to patients with D-dimer ≤ 2 times upper limit of normal range 2.29; 95% CI 1.75--2.98) [@bib0080]. For VTE recurrence prediction after a few months of anticoagulant treatment for a first idiopathic VTE, D-dimer levels -- on anticoagulation or after anticoagulation cessation -- have been extensively explored and included in all predictive models such as the Vienna Prediction Model, the HERDOO2 score, the DASH tool and the DAMOVES score [@bib0055].

Finally, the role of D-dimer as a prognostic tool has also been assessed, mainly in the setting of acute VTE. In a retrospective study published in 2006, Aujesky et al. showed that among patients with confirmed PE (*n*  = 366), those who died had higher median D-dimer levels than patients who survived (4578 versus 2946 μg/L;   *p*= 0.005). All-cause mortality increased with increasing D-dimer levels, rising from 1.1% in the first quartile (\<1500 μg/L) to 9.1% in the fourth quartile (\>5500 μg/L) (  *p*= 0.049) [@bib0085]. These findings were recently confirmed in the COMMAND-VTE registry (*n*  = 2852): D-dimer levels were again an independent predictor of all-cause mortality in patients with acute VTE. Indeed, mortality at 30 days was of 1.2% in the first quartile (\<4900 μg/L), 2.2% in the second quartile (5000--9900 μg/L), 3.4% in the third quartile (10,000--19,900 μg/L) and 8.4% in the fourth quartile (DD ≥ 20,000 μg/L) [@bib0090].

In this issue, Frère et al. present the results of a systematic review and pooled analysis of available data on the association between D-dimer levels and mortality in 1355 hospitalized patients with coronavirus disease 2019 (COVID-19). As in the setting of acute VTE, higher D-dimer levels were shown to be associated with an increased all-cause mortality in the presented cohorts of patients with COVID-19. Of note, the increase in D-dimer levels did not seem to be the result of overt-DIC in these patients.

A high risk of VTE has been reported over the last few weeks in patients with severe COVID-19 (around 20--40% depending on the local systematic screening strategy) [@bib0095], [@bib0105], which prompted physicians to empirically increase prophylactic anticoagulant dosing. Whether an intensified anticoagulant treatment -- partly tailored to D-dimer levels -- will impact mortality in these patients is currently under investigation in at least four randomised trials (COVID-HEP [NCT04345848](NCT04345848){#intr0005}; IMPROVE [NCT04367831](NCT04367831){#intr0010}; COVI-DOSE [NCT04373707](NCT04373707){#intr0015}; RAPID COVID COAG [NCT04362085](NCT04362085){#intr0020}).

Altogether, the recent data including those presented by Frère et al. in this issue highlight once again the great interest of D-dimer as a biomarker in clinical practice, not only as a diagnostic tool but also as a prognostic tool [@bib0100].
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